Posted AT 12:21 PM EST on 16/02/06
Labopharm loss widens
Labopharm Inc. had a fourth-quarter loss of $11.1-million and $2.4-million in revenues as the drug developer received higher licensing fees and the first sales revenues from its once-daily painkiller drug.
The company also received $30-million in cash related to up front and milestone payments from licensing and distribution agreements, although less than $2-million could be recognized during the quarter as licensing revenue.
The full text of this article has 270 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
